Louisiana State Employees Retirement System Purchases 100 Shares of Cambrex Corp. (CBM)
Louisiana State Employees Retirement System boosted its position in shares of Cambrex Corp. (NYSE:CBM) by 0.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,200 shares of the company’s stock after buying an additional 100 shares during the period. Louisiana State Employees Retirement System’s holdings in Cambrex Corp. were worth $735,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bayesian Capital Management LP bought a new stake in Cambrex Corp. during the first quarter worth approximately $276,000. Aperio Group LLC boosted its stake in Cambrex Corp. by 3.0% in the first quarter. Aperio Group LLC now owns 7,576 shares of the company’s stock worth $333,000 after buying an additional 221 shares in the last quarter. Glenmede Trust Co. NA boosted its stake in Cambrex Corp. by 15.7% in the first quarter. Glenmede Trust Co. NA now owns 11,888 shares of the company’s stock worth $522,000 after buying an additional 1,612 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Cambrex Corp. by 106.5% in the second quarter. BNP Paribas Arbitrage SA now owns 10,385 shares of the company’s stock worth $537,000 after buying an additional 5,356 shares in the last quarter. Finally, Capstone Asset Management Co. boosted its stake in Cambrex Corp. by 11.8% in the second quarter. Capstone Asset Management Co. now owns 13,070 shares of the company’s stock worth $676,000 after buying an additional 1,380 shares in the last quarter. Institutional investors and hedge funds own 99.46% of the company’s stock.
Cambrex Corp. (NYSE:CBM) traded up 0.18% during mid-day trading on Monday, reaching $45.25. The company had a trading volume of 147,190 shares. Cambrex Corp. has a 12 month low of $29.50 and a 12 month high of $59.41. The stock’s 50-day moving average is $44.91 and its 200 day moving average is $47.83. The firm has a market capitalization of $1.45 billion, a P/E ratio of 22.88 and a beta of 1.57.
Cambrex Corp. (NYSE:CBM) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.68 EPS for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.09. The business had revenue of $118.22 million for the quarter, compared to analyst estimates of $114.85 million. Cambrex Corp. had a return on equity of 24.86% and a net margin of 13.97%. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.63 EPS. On average, analysts predict that Cambrex Corp. will post $2.56 earnings per share for the current fiscal year.
Separately, Zacks Investment Research cut Cambrex Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, June 29th.
About Cambrex Corp.
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corp. (NYSE:CBM).
Receive News & Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.